Compared: Device Regulations in Japan, China, and UK
Regulations for the development of medical devices in Japan, China, and the UK will come under scrutiny
Regulations for the development of medical devices in Japan, China, and the UK will come under scrutiny during a workshop to be held in London on March 20.
The Asia-Pacific Technology Network is organizing the event, with the support of Global Regulatory Services (GRS). Among the speakers will be David Jefferys, MD, Senior Vice-President of Eisai Medical Research and the former Chief Executive and Director of the UK Medical Devices Agency of the Department of Health. He will discuss medical device regulations in Japan, including recent developments and combination products.
By 2017, the global medical device market will be worth around US $434.4 billion, amounting to an annual average growth of 7.1% from 2012, and increasing numbers of devices are hybrids, which combine a device with a medicine, according to the organizers. Pre-filled syringes are an example of a combination product.
“Pharma companies can no longer rely on discovering the next blockbuster, and they are being forced to diversify in order to remain viable; therefore, many are now turning to devices as their next revenue stream. Increasing healthcare costs are helping to drive the growing medical device industry,” they noted in a statement.
For further details on the workshop, contact [email protected]
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
